Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection

Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis

“…Of these, 22 were further excluded because six studies did not include HCC patients, four studies did not valuate statin use as exposure, seven studies did not evaluate mortality or recurrence outcomes in HCC patients, two studies did not contain available data for the multivariate adjusted association between statin use and clinical outcomes in HCC patients, and the remaining three were abstracts of already included studies. Finally, nine studies were included [11][12][13][14][15][16][17]25,26].…”

“…Since two studies reported data according to HBV infection status of the patients [11,12], and one of them also reported stratified data according to the TNM stages of the tumor [11], these datasets were included separately. Overall, nine retrospective cohort studies including 62,273 HCC patients from China [11,12,16,25], Japan [14,15], Korea [26], and the United States [13,17] were included. The mean age of the included patients varied from 54 to 67 years, with proportions of male ranging from 64% to 99%.…”

“…The mean age of the included patients varied from 54 to 67 years, with proportions of male ranging from 64% to 99%. Five studies included patients after curative treatments [14][15][16]25,26], two studies included patients with palliative treatments [11,12], while the remaining two studies included patients with either treatments [13,17]. Statin use was validated by prescription records in all of the included studies and defined by accumulative statin dose of ≥28 to 30 cumulative defined daily dose (cDDD) in most studies [11,12,[14][15][16]26].…”

“…Pooled results of 15 datasets from 7 studies [11][12][13][14][15][16][17] using a randomized-effect model showed that statin use was associated with a reduced risk of all-cause mortality in patients with HCC (RR: 0.81, 95% CI: 0.74-0.88, P < 0.001; Figure 2A) with significant heterogeneity (P for Cochrane's Q test <0.001, I 2 = 63%). Sensitivity analyses by omitting one datasets at a time did not significantly change the results (RR: 0.79-0.84, P all <0.05).…”

“…Sensitivity analyses by omitting one datasets at a time did not significantly change the results (RR: 0.75-0.81, P all < 0.05). Pooled results of five studies [14][15][16]25,26] showed that statin use was associated with a reduced HCC recurrence in patients after curative therapy (RR: 0.55, 95% CI: 0.43-0.69, P < 0.001; Figure 4B). Sensitivity analyses by omitting one datasets at a time showed consistent results (RR: 0.45-0.59, P all < 0.05).…”